AH Equity Partners Bio II, L.L.C.
CIK: 0001725722
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (100.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NAUT
Nautilus Biotechnology, Inc.
10% Owner
Discretionary Trading P&L
Holdings
About AH Equity Partners Bio II, L.L.C.
AH Equity Partners Bio II, L.L.C. (SEC CIK 0001725722) files insider reports with the SEC as 10% Owner of Nautilus Biotechnology, Inc. (NAUT).
Signal8 holds 1 ownership filing by AH Equity Partners Bio II, L.L.C., a Form 4, filed on Jun 4, 2026. Those filings report 2 transactions, the latest on Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on AH Equity Partners Bio II, L.L.C.'s filings is in MENLO PARK, CA.
Recent filings by AH Equity Partners Bio II, L.L.C.
- Jun 2, 2026: Open-market sales of NAUT shares (2 lines, Form 4, code S).
Other insiders filing for Nautilus Biotechnology, Inc. (NAUT)
- Posard Matthew L., Director
- NAZEM FARZAD, Director
- Akinsanya Karen, Director
- McIlwain Matthew S, Director
- Epperly Melissa B,, Director
- Patel Sujal M, CEO, President, and Secretary